ELSEVIER

Author Index for Volume 18

Aalto P, 140
Adams HP Jr, 358
Adams J, 14
Azen SP, 168

Babiker AG, 1, 460
Barton FB, 420
Baum M, 1
Bendixen BH, 358
Blackstone EH, 488
Block JE, 54
Bonadonna G, 1
Bonds DR, 420
Bouckaert A, 58
Boyd NF, 241
Brody BA, 602
Brown MB, 445
Buchwald H, 478
Burkham-Kreitner S, 383
Buyse M, 1

Califf RM, 651
Campeau L, 318
Canadian Lung Oncology Group, 27
Canner PL, 318
Cannon C, 517
Cappelleri JC, 431
Chamberlain RM, 228
Clarke M, 1
Clarke WR, 358
Colby C, 251
Collins R, 1
COMMIT Research Group, 131
Cook DJ, 27, 121
Corle DK, 131
Crott R, 58

Dalesio O, 1
Darbyshire JH, 1, 460
Davies C, 1
Davis CE, 557
Davis PH, 358
DeMets DL, 637
Dixon DO, 87
Doll R, 1
Donaldson C, 464
Donta S, 397
Drescher C, 251
Dunn M, 168

Elbourne D, 1
Ellenberg SS, 628
Etzioni R, 251

Farkouh ME, 568
Feldman HA, 380
Flather MD, 568
Fleishman S, 286
Frankowski RF, 228
Freedman LS, 131
Frick MH, 93

Gail MH, 131
Geller NL, 222, 318, 420
Gent M, 546
Geraci E, 621
Glasziou PP, 464
Goetghebeur E, 187
Goldhirsch A, 1
Gray R, 1
Green MR, 286
Green SB, 131, 306, 506
Greenberg C, 241
Grimsman KJ, 358
Guyatt GH, 27

Haber H, 93
Hakama M, 140
Hall J, 464
Hemminki E, 140
Herndon JE II, 286
Hertert S, 328
Hill C, 1
Hill K, 328
Hodis HN, 168
Hofstetter CR, 383
Hokkanen T, 140
Hovell MF, 383
Huhtala H, 140
Hunninghake DB, 328

Insull W, 84
Ioannidis JPA, 431
Iwane M, 65, 397

Jones JA, 383
Jylhä M, 140

Kalish LA, 380
Karjalainen S, 140
Karnash SL, 651
Karrison TG, 151
Keating K, 383
Kesäniemi YA, 93
King D, 27
Kirklin JW, 488
Knatterud GL, 318, 514
Korn EL, 275
Kosty MP, 286
Kristal AR, 241
Kriukov V, 241

Lachenbruch PA, 381
Lau J, 431
Leon AC, 378
Liang W-M, 445
Lipid Study Group, 464
Lockwood GA, 241
Lovato LC, 328
Love BB, 358

Machin D, 301
Mack WJ, 168
Manninen V, 93
Martin LJ, 241
McMahon RP, 420
Moinpour CM, 311
Morrison TC, 383
Musa D, 14

Naftel DC, 488
Nawrocki JW, 93
Ng J, 204
Nieminen MS, 93

O'Brien BJ, 121
O'Brien PC, 222
O'Neill RT, 550

Palensky J, 65
Parmar M, 1
Pasternack A, 93
Peduzzi P, 397
Peele P, 14
Pelusio RM, 461

Controlled Clinical Trials 18:667–668 (1997)
© Elsevier Science Inc. 1997
655 Avenue of the Americas, New York, NY 10010

0197-2456/97/$17.00
PII S0197-2456(97)00136-0

Peto R, 1
Peto TEA, 460
Plante K, 65
Pocock SJ, 530
Pogue J, 568, 580
Prentice RL, 561
Probstfield JL, 328

Quan H, 204

Rosenkranz G, 43
Russos S, 383
Rutqvist L, 1

Sackett D, 1
Sacks HS, 431
Scott CB, 277
Second Joint Meeting of the Society for Clinical Trials and the International Society of Clinical Biostatistics (Abstracts), 18(3S):41S
Shatuck AL, 241
Silverman M, 14
Simes RJ, 464
Slymen DJ, 383
Stampfer M, 494
Stepanavage ME, 204
Stewart H, 1
Suchanek Hudmon K, 228
Syvänne M, 93

Taskinen M-R, 93
Temple RJ, 613
Terrin ML, 420, 500
Thompson B, 318
Tognoni G, 621
Troyan S, 27
Tuimala R, 140
Turner ME, 488

Urban N, 251

Valagussa P, 1
Vrijens B, 187

Waclawiw MA, 420
Wahlgren DR, 383
Waller LA, 180
Walter SD, 27
Wasek PA, 358
Wichman A, 271
Willan AR, 121
Williams GW, 661
Woodlief LH, 651
Woolson RF, 358

Yusuf S, 568, 580, 594

Zakarian J, 383
Zhang J, 204
Zucker D, 318

ELSEVIER

Subject Index for Volume 18

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
AIDS Clinical Trials (book review), 460

ACTIVE CONTROL
When Are Clinical Trials of a Given Agent vs. Placebo No Longer Appropriate or Feasible?, 613

ACUTE TREATMENT
Clinical Perspectives on the Use of Composite Endpoints, 517
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

ADHERENCE
Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

ADJUDICATORS
Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27

ADOLESCENTS
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attention Bias, 383

AGED
Recruiting Older Adults for Clinical Trials, 14

α-LEVEL
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

ALTERNATE ASSIGNMENT
A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180

ANALYSIS
Errors, Misunderstandings, and Fraud, 661
Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27

ANGIOGRAPHIC ENDPOINTS
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

ANTITHROMBOTIC THERAPY
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

APPROVAL
Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs (book review), 271

ASSESSMENT
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306
Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes, 241
Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121
Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27

ATHEROSCLEROSIS
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

Controlled Clinical Trials 18:669–682 (1997)
© Elsevier Science Inc. 1997
655 Avenue of the Americas, New York, NY 10010

0197-2456/97/$17.00
PII S0197-2456(97)00137-2

ATTRITION BIAS
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

AUDITING
Errors, Misunderstandings, and Fraud, 661

BAYESIAN METHODS
Bayesian Methods and F.hics in a Clinical Trial Design (book review), 87

BEHAVIORAL MODIFICATION
Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification, 500
Observational Epidemiology is the Preferred Means of Evaluating Effects of Behavioral and Lifestyle Modification, 494

BENEFIT-RISK RATIO
Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121

BIAS
Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence, 637
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

BIBLIOGRAPHY
Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography, 328

BINARY LONGITUDINAL DATA
Comparing Compliance Patterns Between Randomized Treatments, 187

BIOMEDICAL STUDIES
A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

BYPASS
An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

CANCER
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306
Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311
A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286
Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228
Quality-Adjusted Survival Analysis of Malignant Glioma Patients, 277
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

CENSORING
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

CHEMOPREVENTION TRIALS
Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

CHOLESTEROL
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

CLINICAL EVIDENCE
Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121

CLINICAL PREDICTIONS
Influence of Study Goals on Study Design and Execution, 488

CLINICAL RESEARCH
Clinical Research in Pharmaceutical Development (book review), 461

CLINICAL TRIALS
AIDS Clinical Trials (book review), 460
An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306
Bayesian Methods and Ethics in a Clinical Trial Design (book review), 87
Clinical Perspectives on the Use of Composite Endpoints, 517
Clinical Trials with Multiple Outcomes: A Statistical Perspective on their Design, Analysis, and Interpretation, 530
Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464
Developing Systems for Cost-Effective Auditing of Clinical Trials, 651
Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311
An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420
Interpretating Tests for Efficacy in Clinical Trials With Multiple Endpoints, 222
A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286
A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180
On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561
Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27
Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228
Patient Managed Clinical Trial, 141
Patient Recruitment in Clinical Trials (book review), 84
Recruiting Older Adults for Clinical Trials, 14
Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography, 328
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251
Why Clinical Trials in the Evaluation of Life Style Evaluation?, 514

CLOT-DISSOLVING DRUGS
Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs (book review), 271

CLUSTERS
Some Issues in the Construction and Use of Clusters of Outcome Events, 546

COHORT MAINTENANCE
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

COMMERCIAL SAMPLE SIZE SOFTWARE
A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

COMMUNITY INTERVENTION TRIAL FOR SMOKING CESSATION (COMMIT)
The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT), 131

COMMUNITY STUDIES
The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506
Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification, 500

COMPARISON
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306
Comparing Compliance Patterns Between Randomized Treatments, 187
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

COMPLIANCE PATTERNS
Comparing Compliance Patterns Between Randomized Treatments, 187
Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

COMPOSITE ENDPOINTS
Clinical Perspectives on the Use of Composite Endpoints, 517
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

COMPUTERIZED ENDPOINT MEASURES
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

CONDITIONAL POWER
An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420

CONTROL GROUP SELECTION
A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180

CORONARY ATHEROSCLEROSIS
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

CORONARY BYPASS SURGERY
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

CORONARY ENDPOINT MEASURES
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

COST EFFECTIVENESS
Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464
Developing Systems for Cost-Effective Auditing of Clinical Trials, 651
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

COVARIATES
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

DATA COLLECTION
Developing Systems for Cost-Effective Auditing of Clinical Trials, 651

DEFERRED CONSENT
Informed Consent: Protection or Obstacle? Some Emerging Issues, 628

DEVICE RANDOMIZED CLINICAL TRIALS
Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478

DIEHL, HAROLD S.
A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180

DIETARY ASSESSMENT
Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes, 241

DIFFERENCE
The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations, 58

DOCTOR-PATIENT RELATIONSHIP
Approaches to Informed Consent, 621

DOSE FINDING
Can We Reduce the Dose of a Vaccine?, 43

DOUBLE BLIND
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431

DRUG TESTING
Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs (book review), 271

EFFICACY
The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT), 131
Interpretating Tests for Efficacy in Clinical Trials With Multiple Endpoints, 222

EMERGENCY TREATMENT
Informed Consent: Protection or Obstacle? Some Emerging Issues, 628

ENDPOINTS
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168
Interpretating Tests for Efficacy in Clinical Trials With Multiple Endpoints, 222
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

EPIDEMIOLOGY
Observational Epidemiology is the Preferred Means of Evaluating Effects of Behavioral and Lifestyle Modification, 494

EQUIPOISE
When Are Placebo-Controlled Trials No Longer Appropriate?, 602

EQUIVALENCE STUDY
Can We Reduce the Dose of a Vaccine?, 43

ERROR
Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence, 637
Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311
Errors, Misunderstandings, and Fraud, 661
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

ETHICS
Approaches to Informed Consent, 621
Bayesian Methods and Ethics in a Clinical Trial Design (book review), 87
Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs (book review), 271
Informed Consent: Protection or Obstacle? Some Emerging Issues, 628
When Are Placebo-Controlled Trials No Longer Appropriate?, 602

EVALUATION
The Advantages of Community-Randomized Trials for

Evaluating Lifestyle Modification, 506
Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478
Why Clinical Trials in the Evaluation of Life Style Evaluation?, 514

EXERCISE
Interpreting Studies of Exercise and Osteoporosis: A Call for Rigor, 54

FAT INTAKE
Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes, 241

FIBRIC-ACID DERIVATIVE
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

FISHER, BERNARD, MD
The Trials of Dr. Bernard Fisher: A European Perspective of an American Episode, 1

FOLLOW-UP
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

FOOD AND DRUG ADMINISTRATION (FDA)
Informed Consent: Protection or Obstacle? Some Emerging Issues, 628
Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478

FOOD FREQUENCY QUESTIONNAIRE
Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes, 241

FRAUD
Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence, 637
Errors, Misunderstandings, and Fraud, 661

GENERALIZED ESTIMATING QUESTIONS
Comparing Compliance Patterns Between Randomized Treatments, 187

GERIATRIC ASSESSMENT
Recruiting Older Adults for Clinical Trials, 14

GLIOMA
Quality-Adjusted Survival Analysis of Malignant Glioma Patients, 277

GRAFT
An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318

HALF-SAMPLE ESTIMATION
A Median-Based Test Under Informative Dropout: The One-Sample Case, 445

HEAD AND NECK CANCER
Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

HEPARINOID
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

HHS REGULATIONS
Informed Consent: Protection or Obstacle? Some Emerging Issues, 628

HIGH DENSITY LIPOPROTEIN CHOLESTEROL
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

HISTORY OF CLINICAL TRIALS
A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180

HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431
A Review of the Design of Vaccine Efficacy Trials and a Proposal for the Design of the VA Cooperative Study of Active Immunotherapy of HIV Infection, 397

HUMAN PANEL ENDPOINT MEASURES
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

HUMAN STUDIES
Observational Epidemiology is the Preferred Means of Evaluating Effects of Behavioral and Lifestyle Modification, 494

HYDRAZINE SULFATE
A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

HYPOTHESIS TESTS
Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

INCOMPETENCE
Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence, 637

INDEX
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

INDIVIDUAL SUBJECT RANDOM ASSIGNMENT
Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification, 500

INFORMATIVE DROPOUT
A Median-Based Test Under Informative Dropout: The One-Sample Case, 445

INFORMED CONSENT
Approaches to Informed Consent, 621
Informed Consent: Protection or Obstacle? Some Emerging Issues, 628
When Are Placebo-Controlled Trials No Longer Appropriate?, 602

INTENT-TO-TREAT
A Review of the Design of Vaccine Efficacy Trials and a Proposal for the Design of the VA Cooperative Study of Active Immunotherapy of HIV Infection, 397

INTERIM MONITORING
An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420

INTERPRETATION
Interpreting Studies of Exercise and Osteoporosis: A Call for Rigor, 54
Interpretating Tests for Efficacy in Clinical Trials With Multiple Endpoints, 222
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

INTERVENTION STUDIES
The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506

IRWIN'S RESTRICTED MEAN
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

ISCHEMIC HEART DISEASE
Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

ISCHEMIC STROKE
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST, 358

LEUKEMIA
A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

LIFESTYLE MODIFICATION
The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506
Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification, 500
Observational Epidemiology is the Preferred Means of Evaluating Effects of Behavioral and Lifestyle Modification, 494
Why Clinical Trials in the Evaluation of Life Style Evaluation?, 514

LIPID TRIAL
Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

LIPOPROTEINS
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

LITERATURE SUMMARY
Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography, 328

LONGITUDINAL STUDY
A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

LUNG CANCER
A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

MAGNESIUM
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580

MANAGEMENT
Patient Managed Clinical Trial, 141

MATCHED PAIRS DESIGN
The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT), 131

MEASUREMENT ERROR
Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311

MEDIAN TEST
A Median-Based Test Under Informative Dropout: The One-Sample Case, 445

MEDICAL THERAPY
Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478

MEDICATION EVENT MONITORING SYSTEMS
Comparing Compliance Patterns Between Randomized Treatments, 187

META-ANALYSIS
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580
Meta-Analysis of Randomized Trials: Looking Back and Looking Ahead, 594
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431
Strengths and Limitations of Meta-Analysis: Larger Studies May Be More Reliable, 568

MISSING DATA
Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311

MISUNDERSTANDING
Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence, 637
Errors, Misunderstandings, and Fraud, 661

MONITORING
Developing Systems for Cost-Effective Auditing of Clinical Trials, 651

MULTIPLE ENDPOINTS
Interpretating Tests for Efficacy in Clinical Trials With Multiple Endpoints, 222
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

MULTIPLE OUTCOME EVENTS
Clinical Trials with Multiple Outcomes: A Statistical Perspective on their Design, Analysis, and Interpretation, 530
On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561
Some Issues in the Construction and Use of Clusters of Outcome Events, 546

MULTIVARIATE FAILURE TIMES
On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561

MYOCARDIAL INFARCTION
Clinical Perspectives on the Use of Composite Endpoints, 517
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580

NEW THERAPY
Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121

NON-SMALL CELL LUNG CANCER
A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

OBSERVATIONAL STUDIES
Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification, 500
Influence of Study Goals on Study Design and Execution, 488

ODDS RATIO
The Odds Ratio (letter), 381

OLDER ADULTS
Recruiting Older Adults for Clinical Trials, 14

ONE-SAMPLE CASE
A Median-Based Test Under Informative Dropout: The One-Sample Case, 445

OSTEOPOROSIS
Interpreting Studies of Exercise and Osteoporosis: A Call for Rigor, 54

OUTCOME ASSESSMENT
Influence of Study Goals on Study Design and Execution, 488
Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27

OUTCOME VARIABLE
The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations, 58

OVARIAN CANCER
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

OVERVIEW
Strengths and Limitations of Meta-Analysis: Larger Studies May Be More Reliable, 568

PALLIATION
Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311

PATIENT MANAGEMENT
Patient Managed Clinical Trial, 141

PATIENT RECRUITMENT
Patient Recruitment in Clinical Trials (book review), 84

Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography, 328

PHARMACEUTICAL DEVELOPMENT
Clinical Research in Pharmaceutical Development (book review), 461

PHARMACOECONOMIC TRIAL
The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations, 58

PHASE III TRIALS
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301

PHONE LINES
Number of Phone Lines for Telephone Randomization (letter), 380

PLACEBO
Informed Consent: Protection or Obstacle? Some Emerging Issues, 628
Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228
When Are Clinical Trials of a Given Agent vs. Placebo No Longer Appropriate or Feasible?, 613
When Are Placebo-Controlled Trials No Longer Appropriate?, 602

POISSON PROCESS
An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420

POST CORONARY ARTERY BYPASS GRAFT
An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318

POWER
The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations, 58
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

PREVENTION TRIALS
Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

PRICING
Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs (book review), 271

PRIMARY ENDPOINTS
Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

PUBLICATION BIAS
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431

***p*-VALUES**
Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

QUALITY CONTROL
Errors, Misunderstandings, and Fraud, 661

QUALITY OF LIFE
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306
Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464
Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311
A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

Quality-Adjusted Survival Analysis of Malignant Glioma Patients, 277

QUANTITATIVE COMPUTERIZED ENDPOINT MEASURES
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

QUESTIONNAIRES
Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes, 241

RANDOM ALLOCATION
The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506

RANDOMIZED CONSENT DESIGN
Informed Consent: Protection or Obstacle? Some Emerging Issues, 628

RANDOMIZED CONTROLLED CLINICAL TRIALS
The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306
Comparing Compliance Patterns Between Randomized Treatments, 187
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580
Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464
Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence, 637
Meta-Analysis of Randomized Trials: Looking Back and Looking Ahead, 594
A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180
Number of Phone Lines for Telephone Randomization (letter), 380
Observational Epidemiology is the Preferred Means of Evaluating Effects of Behavioral and Lifestyle Modification, 494
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431
A Review of the Design of Vaccine Efficacy Trials and a Proposal for the Design of the VA Cooperative Study of Active Immunotherapy of HIV Infection, 397
Some Issues in the Construction and Use of Clusters of Outcome Events, 546
Strengths and Limitations of Meta-Analysis: Larger Studies May Be More Reliable, 568
Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478
When Are Clinical Trials of a Given Agent vs. Placebo No Longer Appropriate or Feasible?, 613

RATIO ESTIMATE
An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318
Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121
The Odds Ratio (letter), 381

RECRUITMENT
Patient Recruitment in Clinical Trials (book review), 84
Recruiting Older Adults for Clinical Trials, 14
Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography, 328

REDUCTION
Can We Reduce the Dose of a Vaccine?, 43

REPORTING
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431

RESTRICTED MEAN
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

RESULTS
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431

RUN-IN
Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

SAMPLING BIAS
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

SCREENING TOOL
Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes, 241
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

SECONDARY ENDPOINTS
Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

SECONDARY OUTCOMES
On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561

SECONDARY PREVENTION
Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

SEQUENTIAL MONITORING
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580
On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561

SIDE EFFECTS
Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121

SIMULATION
The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations, 58
An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

SMOKING
The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506
The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT), 131

SOFTWARE
Software Review, 378, 184
A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

STATISTICAL METHODS
The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204
An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318
Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

STOCHASTIC PROCESSES
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580

STOCHASTIC SIMULATION MODEL
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

STREPTOKINASE
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580

STROKE
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

STUDY DESIGN
Bayesian Methods and Ethics in a Clinical Trial Design (book review), 87
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168
Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358
The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT), 131
Errors, Misunderstandings, and Fraud, 661
Influence of Study Goals on Study Design and Execution, 488
Recruitment for Controlled Clinical Trial: Literature Summary and Annotated Bibliography, 328
The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431
A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

STUDY GOALS
Influence of Study Goals on Study Design and Execution, 488

SUMMARY STATISTICS
Comparing Compliance Patterns Between Randomized Treatments, 187

SURGERY
An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318
A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93
Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478

SURVIVAL ANALYSIS
Assessing Quality of Life in Comparative Cancer Clinical Trial: Does It Make A Difference?, 275, 301
Assessing Quality of Life in Comparative Cancer Clinical Trial: Does It Make A Difference? A Discussion, 275, 301, 306
Quality-Adjusted Survival Analysis of Malignant Glioma Patients, 277
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151
A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

TELEPHONE RANDOMIZATION
Number of Phone Lines for Telephone Randomization (letter), 380

THROMBOLYSIS
Clinical Perspectives on the Use of Composite Endpoints, 517
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta- Analysis, 580
When Are Placebo-Controlled Trials No Longer Appropriate?, 602

TOAST
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

TOBACCO CONTROL
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

TRACKING
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

TREATMENT GROUPS
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

USER REVIEW
A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

VACCINE TRIALS
Can We Reduce the Dose of a Vaccine?, 43
A Review of the Design of Vaccine Efficacy Trials and a Proposal for the Design of the VA Cooperative Study of Active Immunotherapy of HIV Infection, 397

VALID INFERENCE
Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

ZUCKER-WITTES MODIFIED RATIO ESTIMATE STATISTICS
An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318